NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis $16.46 -0.66 (-3.83%) As of 01:51 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Summit Therapeutics Stock (NASDAQ:SMMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Summit Therapeutics alerts:Sign Up Key Stats Today's Range$16.25▼$17.4650-Day Range$12.43▼$18.4252-Week Range$12.07▼$29.23Volume2.30 million shsAverage Volume4.37 million shsMarket Capitalization$13.13 billionP/E RatioN/ADividend YieldN/APrice Target$25.91Consensus RatingHold Company Overview Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cancer. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition against PD-1 with selective inhibition of vascular endothelial growth factor A (VEGF-A). Summit is evaluating ivonescimab in clinical studies involving patients with non-small cell lung cancer and other solid tumors. Summit has entered into a licensing and collaboration agreement with Akeso, a biotechnology company that discovered and developed ivonescimab. Under the arrangement, Summit is responsible for advancing the therapy in markets outside specified territories, including China, while Akeso continues development and commercialization activities in its retained regions. The companies are studying ivonescimab both as a standalone treatment and in combination with other cancer therapies. The company has historical roots in the development of therapies for serious infectious diseases but has since concentrated its business primarily on oncology. Summit Therapeutics is headquartered in Miami, Florida, and its shares trade on the Nasdaq Global Select Market under the symbol SMMT. Robert W. Duggan serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Summit Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreSMMT MarketRank™: Summit Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 533rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSummit Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 1 strong buy rating, 6 buy ratings, 9 hold ratings, and 1 sell rating.Upside PotentialSummit Therapeutics has a consensus price target of $25.91, representing about 54.1% upside from its current price of $16.81.Amount of Analyst CoverageSummit Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Summit Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($1.20) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -15.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -15.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 19.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Summit Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.40% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 6.62.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 10.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.32 News SentimentSummit Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Summit Therapeutics this week, compared to 5 articles on an average week.Search Interest31 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.MarketBeat Follows12 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders83.50% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.61% of the stock of Summit Therapeutics is held by institutions.Read more about Summit Therapeutics' insider trading history. Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SMMT Stock News HeadlinesHARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract ...September 22 at 8:24 AM | marketscreener.comMBarclays Keeps Their Hold Rating on Summit Therapeutics (SMMT)September 22 at 8:24 AM | theglobeandmail.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 23 at 1:00 AM | Banyan Hill Publishing (Ad)HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026September 22 at 7:00 AM | businesswire.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 22 at 4:15 AM | americanbankingnews.comSummit Therapeutics: It's Okay Not To Have An AnswerSeptember 17, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)September 15, 2026 | theglobeandmail.comUpdated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian PatientsSeptember 15, 2026 | businesswire.comSee More Headlines SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed this year? Summit Therapeutics' stock was trading at $17.49 at the beginning of the year. Since then, SMMT shares have decreased by 3.9% and is now trading at $16.8130. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (NASDAQ:SMMT) released its quarterly earnings data on Thursday, July, 23rd. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.01. Read the conference call transcript. When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Summit Therapeutics' top institutional investors include BlackRock Inc. (1.19%), Bank of America Corp DE (0.11%), Elmind Capital LP (0.06%) and Wellington Management Group LLP (0.06%). Insiders that own company stock include Mahkam Zanganeh, Robert W Duggan, Yu Xia, Manmeet Singh Soni and Ankur Dhingra. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings7/23/2026Today9/23/2026Next Earnings (Estimated)10/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SMMT's financial health is in the Yellow zone, according to TradeSmith. SMMT has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SMMT CIK1599298 Webwww.smmttx.com Phone650-460-8308Fax44-12-3544-3999Employees265Year Founded2003Price Target and Rating Average Price Target for Summit Therapeutics$25.91 High Price Target$40.00 Low Price Target$11.90 Potential Upside/Downside+59.4%Consensus RatingHold Rating Score (0-4)2.41 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.08 billion Net MarginsN/A Pretax MarginN/A Return on Equity-168.94% Return on Assets-141.92% Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book19.13Miscellaneous Outstanding Shares797,750,000Free Float131,629,000Market Cap$12.97 billion OptionableOptionable Beta-1.24 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:SMMT) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
